Up­dat­ed: Bay­er cuts PhII or­phan drug as it ups R&D spend­ing, ques­tions swirl around new CEO’s next moves

Bay­er has shut­tered a Phase II pro­gram that the EMA had des­ig­nat­ed an or­phan drug “for sci­en­tif­ic rea­sons,” the Ger­man con­glom­er­ate dis­closed in its half-year re­port.

The cut comes as Bay­er re­ports phar­ma earn­ings that are be­low the pri­or year — de­spite “sta­ble sales” — due to “high­er R&D in­vest­ments in cell and gene ther­a­py and chemo­pro­teomics tech­nolo­gies, as well as in projects in ad­vanced clin­i­cal de­vel­op­ment.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER